Abstract
PGHS-1 and PGHS-2 are the targets of nonsteroidal anti- inflammatory drugs (NSAIDs). It appears that the high degree of selectivity for inhibition of PGHS-2 shown by certain compounds is the result of two mechanisms (time-dependent and time-independent inhibition), by which they interact with each isoform. The fenamic acids can be divided into competitive inhibitors of substrate binding and competitive inhibitors that cause time-dependent losses of cyclooxygenase activity. The cyclooxygenase activity was measured by oxygen consumption following preincubation of the enzyme and the inhibitor for increasing periods of time. The rate constants associated with binding inhibition kinetics and structure-activity relationships were calculated for a large number of fenamates, diclofenac and indomethacin. The KI* values are similar but the individual rate constants are markedly different: KI is two-fold lower, and k2 is six-fold slower for diclofenac than for indomethacin. All the active time-dependent compounds show MEPs with a negative conical surface, with their vertex on the minimum of the carboxyl group, which extends around the first aromatic ring to the central region. The conical surface keeps an open angle of 61° or larger, and a close contact surface with the residues Ala527, Ileu523, Val349, and Ser530, in the zones surrounding the bridging amino group and the chlorine atoms for meclofenamate and diclofenac, or in the region around the carbonyl group for indomethacin. The KI* and IC50 values indicate that the interactions that promote the slow binding kinetics must be examined in relation to the reaction energies of formation (ΔHr) of an ionic bond between the deprotonated carboxylic acid group of acid NSAIDs with the monocationic guanidinum group of Arg120, the free energies of solvation in aqueous solution, and the molecular volumes measured. Presumably indomethacin, diclofenac and meclofenamate cause the enzyme to undergo a subtle conformational change to a form that binds compounds even more tightly, with some slight structural changes confined to reorientations of the Arg277 and Gln358 side chains. These results show that the model has reliably chosen regions of biological significance consistent with both the X-ray crystallographic and kinetic results.
Similar content being viewed by others
References
Earnest, D.L., Hixson, L.J. and Alberts, D.S., J. Cell. Biochem. Suppl., 161 (1992) 156.
Kargman, S.L., O'Neill, G.P., Vickers, P.J., Evans, J.F., Mancini, J.A. and Jothy, S., Cancer Res., 55 (1995) 2556.
Smith, W.L., Marnett, L.J. and DeWitt, D.L., In Taylor, C.W. (Ed.) Pharmacological Therapy, Vol. 49, Pergamon Press, London, 1991, pp. 153–179.
Lecomte, M., Laneuville, O., Ji, C., DeWitt, D.L. and Smith, W.L., J. Biol. Chem., 269 (1994) 13207.
Kulmacz, R.J. and Wang, L.-H., J. Biol. Chem., 270 (1995) 24019.
Barnett, J., Chow, J., Ives, D., Chiou, M., Mackenzie, R., Osen, E., Nguyen, B., Tsing, S., Bach, C., Freire, J., Chan, H., Sigal, E. and Ramesha, C., Biochim. Biophys. Acta, 1209 (1994) 130.
Ouellet, M. and Percival, D., Biochem. J., 306 (1995) 247.
Scherrer, A., In Rainsford, K.D. and Path, M.R.C. (Eds.) Anti-Inflammatory and Anti-Rheumatic Drugs, Vol. 2, CRC Press, Boca Raton, FL, 1985, pp. 65–85.
Picot, D., Loll, P.J. and Garavito, R.M., Nature, 367 (1994) 243.
Loll, P.J., Picot, D. and Garavito, R.M., Nature Struct. Biol., 2 (1995) 637.
Loll, P.J., Picot, D., Ekabo, O. and Garavito, R.M., Biochemistry, 35 (1996) 7330.
Kulmacz, R.J. and Lands, W.E.M., In Benedetto, C., Mc-Donald Gibson, R.G., Nigam, S. and Slater, T.F. (Eds.), Prostaglandin and Related Substances: A Practical Approach, IRL Press, Washington, DC, 1987, pp. 209–227.
Watnick, A.S., Taber, R.I. and Tabachnick, I.A., Arch. Int. Pharmacodyn., 190 (1971) 78.
Callan, O.H., On-Yee, S. and Swinney, D.C., J. Biol. Chem., 271 (1996) 3548.
Lozano, J.J., Pouplana, R., López, M. and Ruiz, J., J. Mol. Struct. (Theochem), 335 (1995) 215.
Moser, P., Sallmann, A. and Wiesenberg, I., J. Med. Chem., 33 (1990) 2358.
Dhanaraj, V. and Vijayan, M., Acta Crystallogr., B44 (1988) 406.
Biosym Technologies, Inc., San Diego, CA.
Kollman, P.A., J. Comput. Chem., 11 (1990) 431.
AMSOL 5.4.1., Oxford Molecular Group.
Frisch, M.J., Head-Gordon, M., Trucks, G.W., Foresman, J.B., Schlegel, H.B., Raghavachari, K., Robb, M.A., Binkley, J.S., Gonzalez, C., Defrees, D.J., Fox, D.J., Whiteside, R.A., Seeger, R., Melius, C.F., Baker, J., Martin, R.L., Kahn, L.R., Stewart, J.J.P., Topiol, S. and Pople, J.A., Gaussian 92, Gaussian Inc., Pittsburgh, PA, 1992.
Sanz, F., Manaut, F., Segura, J.J., Carbó, M. and De la Torre, R., J. Mol. Struct. (Theochem), 170 (1988) 171.
Sobolev, V., Wade, R.C., Vriend, G. and Edelman, M., Proteins Struct. Funct. Genet., 25 (1996) 120.
GRID v.15, Molecular Discovery Ltd., Elms Parade, Oxford, 1997.
Goodford, P.J., J. Med. Chem., 28 (1985) 849.
Kulmacz, R.J., Pendleton, R.B. and Lands, W.E.M., J. Biol. Chem., 269 (1994) 5527.
Ferenczy, G.G., Reynolds, C.A. and Richards, W.G., J. Comput. Chem., 11 (1990) 159.
Lozano, J.J., López, M., Ruiz, J., Vazquez, I.J. and Pouplana, R., In Wermuth, C.G. (Ed.) Trends in QSAR and Molecular Modelling'92, ESCOM, Leiden, 1993, pp. 560–562.
Bhattacharyya, D.K., Lecomte, M., Rieke, C.J., Garavito, M. and Smith, W.L., J. Biol. Chem., 271 (1996) 2179.
Mancini, J.A., Riendeau, D., Falgueyret, J.P., Vickers, P.J. and O'Neill, G.P., J. Biol. Chem., 270 (1995) 29372.
Kulmacz, R.J., Palmer, G. and Ah-Lim, T., Mol. Pharm., 40 (1991) 833.
Ah-Lim, T., Kulmacz, R.J. and Palmer, G., J. Biol. Chem., 270 (1995) 10503.
Ruiz, J., López, M., Milà, J., Lozoya, E., Lozano, J.J. and Pouplana, R., J. Comput.-Aided Mol. Design, 7 (1993) 183.
López, M., Lozoya, E., Ruiz, J., Milà, J. and Pouplana, R.A., In Silippo, C. and Vittoria, A. (Eds.) QSAR: Rational Approaches to the Design of Bioactive Compounds, Elsevier, Amsterdam, 1991, pp. 315–318.
Mitchell, J.A., Akarasereenont, P., Thiemermann, C., Flower, R.J. and Vane, J.R., Proc. Natl. Acad. Sci. USA, 90 (1994) 11693.
Meade, E.A., Smith, W.L. and DeWitt, D.L., J. Biol. Chem., 268 (1993) 6610.
Kurumbail, R.G., Stevens, A.M., Gierse, J.K., McDonald, J.J., Stegeman, R.A., Pak, J.Y., Gildehaus, D., Miyashiro, J.M., Penning, T.D., Seibert, K., Isakson, P.C. and Stallings, W.C., Nature, 384 (1996) 644.
Kulmacz, R.J. and Lands, W.E.M., J. Biol. Chem., 260 (1985) 12572.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pouplana, R., Pérez, C., Sánchez, J. et al. The structural and electronical factors that contribute affinity for the time-dependent inhibition of PGHS-1 by indomethacin, diclofenac and fenamates. J Comput Aided Mol Des 13, 297–313 (1999). https://doi.org/10.1023/A:1008094616324
Issue Date:
DOI: https://doi.org/10.1023/A:1008094616324